Company Orphazyme A/S

Equities

ORPHA

DK0062502894

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 11:35:18 2024-03-27 am EDT 5-day change 1st Jan Change
1,200 DKK +0.84% Intraday chart for Orphazyme A/S +2.55% -9.79%

Business Summary

Orphazyme A/S, formerly Orphazyme ApS, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company's candidate, arimoclomol, stimulates the production of the cells? protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells? recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.

Number of employees: 1

Managers

Managers TitleAgeSince
Chief Executive Officer 46 23-05-16

Members of the board

Members of the board TitleAgeSince
Director/Board Member 43 23-05-16
Chairman 53 23-05-16
Chief Executive Officer 46 23-05-16

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 35,312 21,033 ( 59.56 %) 0 59.56 %

Shareholders

NameEquities%Valuation
Danske Bank A/S (Investment Management)
0.0623 %
22 0.0623 % 4 071 kr
SPSW Capital GmbH
0.0510 %
18 0.0510 % 3 331 kr
Advice Capital A/S
0.002832 %
1 0.002832 % 185 kr

Company contact information

Orphazyme A/S

Ole Maaløes Vej 3

2200, Copenhagen

+45 70 70 29 80

http://www.orphazyme.com
address Orphazyme A/S(ORPHA)